The life science and biotech PR distribution service

Coriolis Pharma Expands its ATMP Development Facilities

Coriolis Pharma Logo

Constructions of new facilities for ATMP formulation development up to biosafety level S2 are in progress and operations are expected to start by Q4 2021.

MARTINSRIED-MUNICH, Germany, June 21, 2021 / B3C newswire / -- Coriolis Pharma, a globally operating service provider and one of the world leaders in formulation research and development of (bio)pharmaceutical drugs, today announced the expansion of its ATMP development facilities under biosafety level S2 (BSL2 / S2).

Re-construction of an existing building near the Coriolis headquarters has started in March this year and the laboratories are planned to be operational in Q4 2021. The new facilities will increase Coriolis’ total floor space to 7,800 m2. The new labs will host the formulation development of ATMPs, cell culture activities, particle characterization and identification, analytical ultracentrifugation and a lyophilization development center for ATMPs.

“Already in 2018, we started strengthening our scientific expertise and offering services for ATMPs and are now pleased to see that this segment experiences a significant growth,” says Dr. Michael Wiggenhorn, CEO of Coriolis Pharma. “That is why we are expanding our capacities in this area with new lab facilities under biosafety level S2.”

Advanced therapy medicinal products (ATMPs) are booming, but ATMP formulations are still far from advanced. Similar to mRNA vaccine, ATMPs either have a very short shelf life (hours to days) or require (ultra) cold storage conditions. A tailored formulation development program, also exploring lyophilization as an option, can remarkably improve this situation.

“To support the lab expansion also from scientific perspective, we recently expanded our Scientific Advisory Board by two distinguished experts in the field: Prof. Ernst Wagner from the Ludwig-Maximilians-Universität (LMU) Munich and Prof. Gideon Kersten from the Leiden University,” explained Dr. Andrea Hawe, CSO of Coriolis Pharma. “Their scientific advice will be extremely valuable to the success of our client projects and will enable us to stay on top of recent development in the field.”

coriolis pharma new atmp facilities small

Caption: Building of the new ATMP facilities of Coriolis Pharma in Martinsried-Munich.

For high resolution please click the image.


About Coriolis Pharma
Coriolis Pharma is a globally operating service provider and one of the world leaders in formulation research and development of (bio)pharmaceutical drugs including proteins, peptides, monoclonal antibodies, nucleic acids, virus-like particles, vaccines, advance therapy medicinal products (ATMPs) and genetically modified organisms (GMOs). Coriolis Pharma develops liquid and lyophilized formulations with all technologies and analytical methods in-house. For each individual project, highly skilled scientists develop tailor-made study designs that align with the clients’ drug development strategy. With science-driven innovative solutions, Coriolis Pharma supports all phases of drug development including troubleshooting, batch-release testing including innovative methods and formulation optimization even beyond market approval. Coriolis Pharma’s mission is: formulating innovation!



Coriolis Pharma Research GmbH
Dr. Daniel Weinbuch
Scientific Marketing Coordinator
+49 (0) 89 4177 60 – 149
This email address is being protected from spambots. You need JavaScript enabled to view it.
Fraunhoferstr. 18b
82152 Martinsried-Munich


Keywords: Laboratories; Facility Design and Construction; Cell Culture Techniques; Research; Drug Compounding; Drug Therapy; Research; Pharmaceutical Preparations; Germany


Published by B3C newswire

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.